Category: by country

A correction to a correction for stem cell researcher Jacob Hanna

Jacob Hanna
Jacob Hanna

A correction to a correction is the latest problem for highly cited researcher Jacob Hanna. The stem cell scientist — whose high-profile work has received scrutiny over the past year — has amended an earlier correction notice after a reader spotted an inadvertent “mistake.”

We reported on the original correction, to the 2009 Cell Stem Cell paper “Metastable Pluripotent States in NOD-Mouse-Derived ESCs,” in July. The paper has been cited 184 times, according to Thomson Scientific’s Web of Knowledge.

Apparently, a pair of images in the original correction note are of the same cell colonies, when they are supposed to be of separate cell colonies.

The new (and detailed) note explains how that happened:

Continue reading A correction to a correction for stem cell researcher Jacob Hanna

EMBO investigation yields two more retractions and three corrections for Voinnet

Olivier Voinnet
Olivier Voinnet

An investigation into the work of Olivier Voinnet by The EMBO Journal has led to another two retractions and three more corrections for the high-profile plant scientist, now suspended from the CNRS for two years.

According to the authors, Voinnet was responsible for some of the errors; all papers have been questioned on PubPeer.

The EMBO J, the flagship publication of the European Molecular Biology Organization, posted four notices earlier today and told Retraction Watch that the notice for the fifth paper would be posted by tomorrow.

This latest round brings our count for Voinnet up to Continue reading EMBO investigation yields two more retractions and three corrections for Voinnet

Judge dismisses defamation suit against diabetes journal

Mario Saad, via unicamp.br
Mario Saad, via unicamp.br

Mario Saad can’t catch a break — yesterday, a Massachusetts judge dismissed his defamation suit against the American Diabetes Association, publisher of Diabetes, which published an expression of concern regarding four of his papers in March.

The researcher has tried — and failed — to use the courts to remove the EoC.

In Saad’s latest attempt to employ legal action against the journal — arguing the EoC was defamatory — the United States District Court of Massachusetts was clear in its ruling (which you can view in its entirety here):

Continue reading Judge dismisses defamation suit against diabetes journal

17 retractions from SAGE journals bring total fake peer review count to 250

sage-journals-logoOn Monday, we reported on 64 new retractions from Springer journals resulting from fake peer reviews. Yesterday, SAGE — which retracted 60 papers for the same reason just over a year ago — added 17 additional retractions to their list.

The articles were published in five different journals, and one retraction involved authorship fraud in addition to peer review fraud, according to a SAGE spokesperson: Continue reading 17 retractions from SAGE journals bring total fake peer review count to 250

Analysis of pilots with prostate cancer retracted for “inappropriate data”

Aerospace Medicine and Human PerformanceIn case any pilots out there are worrying about their risk of prostate cancer based on a recent meta-analysis that found they are at least twice as likely to develop the disease, they should relax — the paper has been retracted.

The reason: “including inappropriate data from two studies that should be ineligible.”

“The risk of prostate cancer in pilots: a meta-analysis” reviewed eight studies to determine whether airline pilots, who are regularly exposed to radiation and other occupational hazards, have a higher incidence of prostate cancer. However, it also included studies that reported on prostate cancer among all U.S. Armed Forces servicemen, not pilots.

The retraction notice was posted in May — only months after it was published in Aerospace Medicine and Human Performance in February. The notice included a letter to the editor outlining flaws in the meta-analysis and an apologetic response from first author, David Raslau at the Mayo Clinic.

Here’s the notice (appearing at the bottom of page 2):

Continue reading Analysis of pilots with prostate cancer retracted for “inappropriate data”

“Exactly the same clinical study” published six times

4A group of researchers conducted a clinical trial on hundreds of hypertensive patients. Then, they published the results…six times.

The “nearly identical” papers came to our attention via a retraction in Inflammation. Editor in chief Bruce Cronstein explained how he learned of the mass duplication:

The editors were contacted en masse by somebody doing a Cochrane Review on hypertension and who noticed that the content of the 6 papers was nearly identical.  Frankly, not one of us would have noticed otherwise.

Another of those papers, in the European Journal of Pharmaceutical Sciences, has also been retracted. That note is similar to the retraction notice for the Inflammation paper, both of which have been cited twice:

Continue reading “Exactly the same clinical study” published six times

Running shoe paper pulled for failing to disclose author’s industry ties

87507315-105.4.coverNot so fast — a paper that showed wearing Vibram FiveFingers (resembling foot gloves) “may help reduce running-related injuries” has been removed after the editors realized the first author is on Vibram’s advisory board.

Managing editor Noelle A. Boughanmi told us there’s no retraction here — the journal is just fixing the paper to address the relationship of podiatrist Nick Campitelli with the company featured in the article.

There is still a copy of the paper on PubMed, which suggests these “minimalist shoes” strengthen key muscles.

The paper was published online by the Journal of the American Podiatric Medical Association. It was removed after editors realized that “the author did not fully disclose some involvement with the company,” Boughanmi said:

Continue reading Running shoe paper pulled for failing to disclose author’s industry ties

Trouble with data proves toxic for a pair of toxicology papers

logoA pair of papers about the risks of titanium dioxide nanoparticles that share many of the same authors has been retracted from a toxicology journal following an investigation at Soochow University in China.

Particle and Fibre Toxicology is retracting the papers for problems with the statistical methods and missing data, as well as for sharing figures.

Here’s the note for “Intragastric exposure to titanium dioxide nanoparticles induced nephrotoxicity in mice, assessed by physiological and gene expression modifications:”

Continue reading Trouble with data proves toxic for a pair of toxicology papers

“Disagreement about the relative contributions” of authors burns capacitor paper

S02663538A 2014 paper on a component for thin electric circuits has been retracted from Composites Science and Technology due to a “disagreement” over author contributions, according to the retraction note.

The retraction note for “Preparation and dielectric properties of BaTiO3:epoxy nanocomposites for embedded capacitor application” is short and sweet. Here it is, in full:

Continue reading “Disagreement about the relative contributions” of authors burns capacitor paper

Gold nanoparticle paper crushed by “deliberate and fraudulent use of data”

8

Biotechnology Letters has retracted a paper on a new gene delivery technique due to “the deliberate and fraudulent use of data in the paper that had previously appeared in other papers of these two authors.”

The journal’s Editor in Chief Colin Ratledge told us that someone tipped him off that one of the authors, University of Kalyani microbiologist Keka Sarkar, had been self-plagiarizing:

I can say that a person who was familiar with the work of Dr Sarkar got in touch with about their concerns about her publications and, in particular, her paper published in Biotechnology Letters.  They supplied a dossier of her publications showing the obvious duplications of figures and that she had been using the same figures in different papers to illustrate the results from supposedly different experiments.

He found that, indeed, multiple figures in the Biotechnology Letters had appeared in other publications of Sarkar’s, some prior to the paper’s October 2013 publication, and one after. The details are in the whole retraction note:
Continue reading Gold nanoparticle paper crushed by “deliberate and fraudulent use of data”